The Small-Molecule Fast Skeletal Troponin Activator, CK-2127107, Improves Exercise Tolerance in a Rat Model of Heart Failure
- 12 February 2015
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in The Journal of pharmacology and experimental therapeutics
- Vol. 353 (1), 159-168
- https://doi.org/10.1124/jpet.114.222224
Abstract
Heart failure–mediated skeletal myopathy, which is characterized by muscle atrophy and muscle metabolism dysfunction, often manifests as dyspnea and limb muscle fatigue. We have previously demonstrated that increasing Ca2+ sensitivity of the sarcomere by a small-molecule fast skeletal troponin activator improves skeletal muscle force and exercise performance in healthy rats and models of neuromuscular disease. The objective of this study was to investigate the effect of a novel fast skeletal troponin activator, CK-2127107 (2-aminoalkyl-5-N-heteroarylpyrimidine), on skeletal muscle function and exercise performance in rats exhibiting heart failure–mediated skeletal myopathy. Rats underwent a left anterior descending coronary artery ligation, resulting in myocardial infarction and a progressive decline in cardiac function [left anterior descending coronary artery heart failure (LAD-HF)]. Compared with sham-operated control rats, LAD-HF rat hindlimb and diaphragm muscles exhibited significant muscle atrophy. Fatigability was increased during repeated in situ isokinetic plantar flexor muscle contractions. CK-2127107 produced a leftward shift in the force-Ca2+ relationship of skinned, single diaphragm, and extensor digitorum longus fibers. Exercise performance, which was assessed by rotarod running, was lower in vehicle-treated LAD-HF rats than in sham controls (116 ± 22 versus 193 ± 31 seconds, respectively; mean ± S.E.M.; P = 0.04). In the LAD-HF rats, a single oral dose of CK-2127107 (10 mg/kg p.o.) increased running time compared with vehicle treatment (283 ± 47 versus 116 ± 22 seconds; P = 0.0004). In summary, CK-2127107 substantially increases exercise performance in this heart failure model, suggesting that modulation of skeletal muscle function by a fast skeletal troponin activator may be a useful therapeutic in heart failure–associated exercise intolerance.This publication has 64 references indexed in Scilit:
- Fast Skeletal Muscle Troponin Activation Increases Force of Mouse Fast Skeletal Muscle and Ameliorates Weakness Due to Nebulin-DeficiencyPLOS ONE, 2013
- Altered sarcoplasmic reticulum calcium cycling—targets for heart failure therapyNature Reviews Cardiology, 2012
- Abnormalities of Calcium Handling Proteins in Skeletal Muscle Mirror Those of the Heart in Humans With Heart Failure: A Shared Mechanism?Journal of Cardiac Failure, 2012
- Activation of fast skeletal muscle troponin as a potential therapeutic approach for treating neuromuscular diseasesNature Medicine, 2012
- Levosimendan improves calcium sensitivity of diaphragm muscle fibres from a rat model of heart failureBritish Journal of Pharmacology, 2010
- Reduced knee extensor function in heart failure is not explained by inactivityInternational Journal of Cardiology, 2010
- Chapter 6 Kinetic and Equilibrium Analysis of the Myosin ATPaseMethods in Enzymology, 2009
- Impaired isotonic contractility and structural abnormalities in the diaphragm of congestive heart failure ratsInternational Journal of Cardiology, 2008
- A neutralizing leptin receptor antibody mitigates hypertrophy and hemodynamic dysfunction in the postinfarcted rat heartAmerican Journal of Physiology-Heart and Circulatory Physiology, 2008
- A structural and kinetic study on myofibrils prevented from shortening by chemical cross-linkingBiochemistry, 1993